Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
Status:
Withdrawn
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to find the optimal dose of balugrastim by
characterizing its pharmacokinetics (PK), and by comparing the pharmacodynamics (PD) of
balugrastim to filgrastim in children receiving chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries